Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aldeyra Therapeutics (ALDX) Misses Q1 EPS by 4c
May 15, 2018 7:32 AM EDTAldeyra Therapeutics (NASDAQ: ALDX) reported Q1 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39).
"We are pleased with our progress in the first quarter, as we continued to advance our product pipeline for the treatment of immunological diseases," stated... More
